A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease

ClinicalTrials.gov ID: NCT07023289

Public ClinicalTrials.gov record NCT07023289. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 21, 2026, 1:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Randomized, Open-Label Study Comparing Telisotuzumab Adizutecan (ABBV-400) Monotherapy to the Current Standard of Care in Subjects With Post Adjuvant ctDNA Positive Colorectal Cancer and No Radiographic Evidence of Disease (NED)

Study identification

NCT ID: NCT07023289
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: AbbVie; Industry
Enrollment: 140 participants

Conditions and interventions

Conditions

Colorectal Cancer

Interventions

Standard of Care Drug
Telisotuzumab Adizutecan Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 1, 2025
Primary completion: Oct 31, 2029
Completion: Oct 31, 2029
Last update posted: May 17, 2026

2025 – 2029

United States locations

U.S. sites: 21
U.S. states: 14
U.S. cities: 20

Facility	City	State	ZIP	Site status
Clearview Cancer Institute - Huntsville - Cci Drive /ID# 278621	Huntsville	Alabama	35805	Recruiting
Providence Medical Foundation - Fullerton /ID# 274207	Fullerton	California	92835-3826	Recruiting
USC Norris Comprehensive Cancer Center /ID# 274550	Los Angeles	California	90033	Recruiting
Mayo Clinic Hospital Jacksonville /ID# 274472	Jacksonville	Florida	32224	Recruiting
Moffitt Cancer Center /ID# 274372	Tampa	Florida	33612	Recruiting
University of Chicago Medical Center /ID# 274742	Chicago	Illinois	60637	Recruiting
Johns Hopkins Hospital /ID# 275645	Baltimore	Maryland	21287	Recruiting
Massachusetts General Hospital /ID# 273608	Boston	Massachusetts	02114	Recruiting
University of Michigan Health System - Ann Arbor /ID# 273511	Ann Arbor	Michigan	48109	Recruiting
Scri Minnesota Oncology Hematology, P.A. /ID# 275149	Minneapolis	Minnesota	55404	Recruiting
Mayo Clinic-Rochester /ID# 273508	Rochester	Minnesota	55905	Recruiting
Northwell Health Center for Advanced Medicine. /ID# 275331	Lake Success	New York	11042	Recruiting
Duke University Medical Center /ID# 279457	Durham	North Carolina	27710	Recruiting
Northwest Cancer Specialists /ID# 275151	Portland	Oregon	97227-1800	Recruiting
SCRI Oncology Partners /ID# 274522	Nashville	Tennessee	37203	Recruiting
Texas Oncology - Central/South Texas /ID# 275154	Austin	Texas	78705	Recruiting
The Center For Cancer And Blood Disorders /ID# 278512	Fort Worth	Texas	76104	Recruiting
Texas Oncology-Grapevine /ID# 275155	Grapevine	Texas	76051	Recruiting
The University of Texas MD Anderson Cancer Center /ID# 273539	Houston	Texas	77030	Recruiting
Inova Schar Cancer Institute - Fairfax - Innovation Park Drive /ID# 274586	Fairfax	Virginia	22031	Recruiting
Virginia Cancer Specialists - Fairfax /ID# 274339	Fairfax	Virginia	22031	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 24 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07023289, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 17, 2026 · Synced May 21, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07023289 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →